Search Results - "Chataway, J."

Identifying barriers to help-seeking for sexual dysfunction in multiple sclerosis by Tudor, Katarina Ivana, Eames, S., Haslam, C., Chataway, J., Liechti, M. D., Panicker, J. N.

“…Background Sexual dysfunction (SD) is common in multiple sclerosis (MS), however, under-reported. Objective The aim of this study was to identify barriers…”
Get full text

2017 McDonald diagnostic criteria: A review of the evidence by McNicholas, N, Hutchinson, M, McGuigan, C, Chataway, J

“…•Multiple sclerosis is diagnosed according to the McDonald Criteria, recently revised in 2017.•Revisions are based on existing evidence, and not expert…”
Get full text

A practical approach to diagnosing adult onset leukodystrophies by Ahmed, R M, Murphy, E, Davagnanam, I, Parton, M, Schott, J M, Mummery, C J, Rohrer, J D, Lachmann, R H, Houlden, H, Fox, N C, Chataway, J

Get full text

Sodium intake and multiple sclerosis activity and progression in BENEFIT by Fitzgerald, Kathryn C., Munger, Kassandra L., Hartung, Hans‐Peter, Freedman, Mark S., Montalbán, Xavier, Edan, Gilles, Wicklein, Eva‐Maria, Radue, Ernst‐Wilhelm, Kappos, Ludwig, Pohl, Christoph, Ascherio, Alberto, Strasser‐Fuchs, S, Berger, T, Vass, K, Sindic, C, Dubois, B, Dive, D, Debruyne, J, Metz, L, Rice, G, Duquette, P, Lapierre, Y, Freedman, M, Traboulsee, A, O'Connor, P, Štourač, P, Talab, R, Zapletalova, O, Kovařova, I, Medova, E, Fiedler, J, Frederiksen, J, Brochet, B, Moreau, T, Vermersch, P, Pelletier, J, Edan, G, Clanet, M, Clavelou, P, Lebrun‐Frenay, C, Gout, O, Kallela, M, Pirttila, T, Ruutiainen, J, Koivisto, K, Villringer, A, Altenkirch, H, Wessel, K, Hartung, H‐P, Steinke, W, Kölmel, H, Oschmann, P, Diem, R, Dressel, A, Hoffmann, F, Baum, K, Jung, S, Petereit, H, Reske, D, Sailer, M, Kohler, J, Sommer, N, Hohlfeld, R, Gold, R, Rieckmann, P, Komoly, R, Jakab, G, Csiba, L, Vecsei, L, Miller, A, Karussis, D, Chapman, J, Ghezzi, A, Comi, G, Cosi, V, Anten, B, Myhr, K‐M, Szczudlik, A, Selmaj, K, Stelmasiak, Z, Podemski, R, Maciejek, Z, Cunha, L, Sega‐Jazbec, S, Montalban, X, Arbizu, T, Saiz, A, Barcena, J, Arroyo, R, Fernandez, O, Izquierdo, G, Casanova, B, Lycke, J, Kappos, L, Mattle, H, Beer, K, Coleman, R, Chataway, J, Riordan, J O, Howell, S

“…Objective To assess whether a high‐salt diet, as measured by urinary sodium concentration, is associated with faster conversion from clinically isolated…”
Get full text

Profiling cognitive–motor interference in a large sample of persons with progressive multiple sclerosis and impaired processing speed: results from the CogEx study by Veldkamp, R., D’hooge, M., Sandroff, B. M., DeLuca, J., Kos, D., Salter, A., Feinstein, A., Amato, M. P., Brichetto, G., Chataway, J., Farrell, R., Chiaravalloti, N. D., Dalgas, U., Filippi, M., Freeman, J., Motl, R. W., Meza, C., Inglese, M., Rocca, M. A., Cutter, G., Feys, P.

“…Background Performing cognitive–motor dual tasks (DTs) may result in reduced walking speed and cognitive performance. The effect in persons with progressive…”
Get full text

Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis by Friede, T., Parsons, N., Stallard, N., Todd, S., Valdes Marquez, E., Chataway, J., Nicholas, R.

“…In recent years adaptive seamless phase II/III designs (ASDs) allowing treatment or dose selection at an interim analysis have gained much attention because of…”
Get full text

Serum Neurofilament Light concentrations are not associated with renal function in secondary progressive multiple sclerosis by Williams, T., Zetterberg, H., Chataway, J.

“…Neurofilament Light (NFL) is a promising biomarker of neuroaxonal injury. Its utility may be improved by expression relative to age-matched controls and by…”
Get full text

NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study by Solanky, B S, John, N A, DeAngelis, F, Stutters, J, Prados, F, Schneider, T, Parker, R A, Weir, C J, Monteverdi, A, Plantone, D, Doshi, A, MacManus, D, Marshall, I, Barkhof, F, Gandini Wheeler-Kingshott, C A M, Chataway, J

“…The secondary progressive phase of multiple sclerosis is characterised by disability progression due to processes that lead to neurodegeneration. Surrogate…”
Get full text

Lymphomatosis cerebri: a treatable cause of rapidly progressive dementia by Samani, Amit, Davagnanam, Indran, Cockerell, Oliver Charles, Ramsay, Alan, Patani, Rickie, Chataway, Jeremy

“…Cerebrospinal fluid (CSF) examination showed a protein level of 0.74 g/L with a glucose of 3.2 mmol/L (serum 5.5 mmol/L), <1 white blood cell per millilitre…”
Get full text

South Asian strokes: lessons from the St Mary's stroke database by Banerjee, S., Biram, R., Chataway, J., Ames, D.

“…Background: South Asians comprise the largest ethnic minority population in the UK. This subgroup is known to have an elevated risk of stroke. However, there…”
Get full text

Human stem cell therapy in ischaemic stroke: a review by Banerjee, Soma, Williamson, Deborah, Habib, Nagy, Gordon, Myrtle, Chataway, Jeremy

“…Stroke is a leading cause of death and disability. Globally, 15 million people suffer a stroke each year, of whom more than 5 million die, and a further 5…”
Get full text

Associations between fatigue impact and physical and neurobehavioural factors: An exploration in people with progressive multiple sclerosis by Connolly, L, Chatfield, S, Freeman, J, Salter, A, Amato, MP, Brichetto, G, Chataway, J, Chiaravalloti, ND, Cutter, G, DeLuca, J, Dalgas, U, Farrell, R, Feys, P, Filippi, M, Inglese, M, Meza, C, Moore, NB, Motl, RW, Rocca, MA, Sandroff, BM, Feinstein, A

“…Fatigue is common in people with multiple sclerosis (MS). Understanding the relationship between fatigue, physical and neurobehavioural factors is important to…”
Get full text

It is better to be in a clinical trial than not: lessons learnt from clinical neurology—the management of acute multiple sclerosis relapses by MCNICHOLAS, N, PATEL, A, CHATAWAY, J

“…To compare being on-, or off-, a randomized controlled trial (RCT) for the same intervention. Cohort study. Ambulatory outpatient clinic in a clinical…”
Get full text

Validating the portal population of the United Kingdom Multiple Sclerosis Register by Middleton, R.M., Rodgers, W.J., Chataway, J., Schmierer, K., Rog, D., Galea, I., Akbari, A., Tuite-Dalton, K., Lockhart-Jones, H., Griffiths, D., Noble, D.G., Jones, K.H., Al-Din, A., Craner, M., Evangelou, N., Harman, P., Harrower, T., Hobart, J., Husseyin, H., Kasti, M., Kipps, C., McDonnell, G., Owen, C., Pearson, O., Rashid, W., Wilson, H., Ford, D.V.

“…•Validation of a self declared MS Population with a clinically diagnosed one.•We analysed the UK MS Register for a number of key characteristics. The internet…”
Get full text

Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis by Manzano, A., Eskyté, I., Ford, H.L., Pavitt, S.H., Potrata, B., Schmierer, K., Chataway, J., Webb, E.J.D., Meads, D., Pepper, G., Bekker, H.L.

“…•Large cohorts of people with RRMS have now taken several Disease-Modifying Treatments.•Switching is a distinctive, rapid and emotional decision-making…”
Get full text

Negotiating the radiologically isolated syndrome by Cummings, A, Chataway, J

“…Multiple sclerosis, always challenging, hands down a particular gauntlet with the concept of the radiologically isolated syndrome. This article discusses what…”
Get full text

Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation by Rakusa, M., Murphy, O., McIntyre, L., Porter, B., Panicker, J., Fowler, C., Scott, G., Chataway, J.

“…Background and purpose To evaluate a dipstick algorithm for urinary tract colonization, prior to high‐dose corticosteroid treatment in acute relapses of…”
Get full text

A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis by Furby, J., Hayton, T., Altmann, D., Brenner, R., Chataway, J., Smith, K. J., Miller, D. H., Kapoor, R.

“…MRI measures of tissue atrophy within the central nervous system may reflect the neurodegenerative process which underpins the progressive phase of multiple…”
Get full text

Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine by Hayton, T., Furby, J., Smith, K. J., Altmann, D. R., Brenner, R., Chataway, J., Hunter, K., Tozer, D. J., Miller, D. H., Kapoor, R.

“…Sodium blockade with lamotrigine is neuroprotective in animal models of central nervous system demyelination. This study evaluated the effect of lamotrigine on…”
Get full text

Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis by Furby, J, Hayton, T, Anderson, V, Altmann, D, Brenner, R, Chataway, J, Hughes, RAC, Smith, KJ, Miller, DH, Kapoor, R

“…Background Neuroaxonal loss is a pathological substrate of disability in progressive multiple sclerosis (MS) and can be estimated in vivo by measuring tissue…”
Get full text